Abstract
Introduction
PALB2 (PArtner and Localizer of BRCA2) is a protein that interacts with BRCA2, stabilizing the intranuclear accumulation of BRCA2 proteins at sites of DNA damage [1] . Biallelic loss of PALB2 causes increased predisposition to cancers, increased sensitivity to DNA damaging agents and Fanconi's Anemia [2] .
Germline PALB2 mutations are rare, but have been reportedly associated with increased predisposition to breast and other cancers. In multiple-breast cancer case families, germline PALB2 mutations have been reported in 1.1% (10 out of 920), 2.7% (3 out of 113), 2.0% (1 out of 50), and 0.6% (5 out of 779) of Western European families in the United Kingdom, Finland, French-Canada, and Australasian, respectively [3] [4] [5] [6] . Within the familial context, germline PALB2 mutations are associated with a 2.3 to 6 fold increased risk to breast cancer [3, 7, 8] . Germline PALB2 mutations have also been reported in unselected female breast cancer cases, but at a lower prevalence (0.9%, 18 out of 1,918 in Finnish breast cancer cases [4] ; 0.5%, 2 out of 356 in French-Canadian breast cancer patients aged <50 years old [5] ; and 0.4%, 5 out of 1,403 in Australian breast cancer patients [6] ). Notably, deleterious germline PALB2 mutations have also been reported in pancreatic cancer cohorts from United States [9] and Europe [10] , but its association with increased risk to ovarian cancer cohorts remains controversial [11, 12] .
Germline PALB2 mutations have also been described in other populations. In a study of Han Chinese, two carriers were identified out of 360 (0.6%) high risk breast cancer patients analysed [13] . Notably, three mutations (1.1%) were reported in a study of PALB2 mutations in 279 African-American patients [14] . Taken together, these data suggests that mutations in PALB2 are rare and may be population-specific.
In this study, we have analysed the prevalence of PALB2 mutations in a cohort of 122 familial breast cancer cases who have previously been tested negative for germline mutations in BRCA1 and BRCA2 and determined the prevalence of selected mutations in a further unselected cohort of breast cancer cases and controls from Malaysia and Singapore.
Materials and Methods

Ethics statement
All study subjects were provided written informed consent. Blood, demographic and family history data was collected from breast cancer patients who consented to participate in this study. The study was approved by the Medical Ethics Committee of University Malaya Medical Centre (UMMC).
Study subjects
(a) Familial breast cancer patients for DNA sequencing. The recruitment of breast cancer patients into the Malaysian Breast Cancer Genetic Study (MyBrCa) started in January 2003 at the University Malaya Medical Centre in Kuala Lumpur. All were histopathology-proven breast carcinoma. From January 2003 to December 2010, a total of 1,220 breast cancer patients were recruited into the MyBrCa study. All index patients were asked about family history of any cancer, including all third degree relatives. Mutation detection for germline BRCA1 and BRCA2 mutations was conducted on 402 individuals by direct DNA sequencing and multiple ligation dependent probe amplification (MLPA) as previously described [15, 16] . Of these, 155 individuals were included in the PALB2 study because they were either (a) diagnosed ≤50 years old and had at least one first-or second-degree relatives with breast cancer; (b) diagnosed with bilateral breast cancer with the primary cancer at age 50 or below; (c) diagnosed with male breast cancer at any age; (d) affected with both breast and ovarian cancers; (e) affected with both breast and pancreatic cancers; or (f) diagnosed with breast cancer and had at least one first-degree relative with pancreatic cancer. Exclusion criteria were a medical history of cancer, acute myocardial infarction or stroke, or major psychiatric morbidity including schizophrenia, psychotic depression, and advanced Alzheimer's Disease. 77% of the participants who were interviewed provided a blood sample.
PALB2 analysis
Sequencing of all the intron-exon junctions and exonic sequences was conducted using Sanger sequencing of genomic DNA extracted from peripheral white blood cells using standard methods. Primer sequences were adapted from several publications (Table S1) [2, 6, 17] .
PALB2 Genotyping
Multiplex genotyping of seven PALB2 mutations identified in exon 4 in this study and an additional two Asian recurrent mutations were performed using high-throughput Sequenom MassARRAY iPLEX platform (Sequenom Inc., San Diego, California, USA). Mutations in other exons were identified after the completion of the genotyping study and were therefore excluded from analyses. All mutations identified were confirmed by direct sequencing in an independent DNA sample.
In silico analysis
In silico analysis of the effect of missense mutations on protein function was determined using Polyphen-2 (Polymorphism Phenotyping version 2) [18] and SIFT (Sorting Tolerant from Intolerant) [19, 20] .
Results
Prevalence of PALB2 germline mutations in familial breast cancer patients
Of the 155 high risk breast cancer patients selected for this study, 20 had germline deleterious mutations in BRCA1 and 13 in BRCA2. The remaining 122 individuals tested negative for BRCA mutations were analyzed for PALB2 germline mutations by direct Sanger sequencing (Table 1 ) and 13 genetic variants were identified (Table 2 ). These included two deleterious mutations (mutation prevalence of 1.6%), ten missense variants of unknown clinical significance and one synonymous variant.
(a) Mutation c.1037_1041 delAAGAA; STOP 358. This truncating mutation was found in a Chinese woman who developed invasive ductal carcinoma at age 38, which was negative for the expression of the estrogen-and HER-2 receptors and positive for the expression of the progesterone- In total, 122 breast cancer patients who were tested negative for germline mutations in BRCA1 and BRCA2 were analyzed for germline mutations in PALB2
by Sanger sequencing. Table 1 shows the distribution of index patients according to their ethnicity, age at diagnosis and family history characteristics.
receptor. She had a maternal aunt who had breast cancer in her 40s (Figure 1 A) .
(b) Mutation c.2606 delC; S869X. This truncating mutation was found in a Chinese woman who developed invasive ductal carcinoma at age 39, which was positive for the expression of both estrogen-and progesterone-receptors and had amplification of HER-2 receptor. Her mother was affected with breast cancer at age 51 (Figure 1 B) .
Evaluation of variants pathogenicity through casecontrol analysis
Rare mutations detected from the sequencing of exon 4 of PALB2 (n=7) and deleterious mutations that were reported to be recurrent in other Asian populations (Chinese PALB2 c.751 C>T and PALB2 c.1250_1251 delAAinsTCT) [13] were tested for in additional cohorts of breast cancer cases and controls by genotyping ( Table 3 ). The cases comprised a hospital-based cohort of 874 breast cancer cases from Malaysia and 532 breast cancer cases from Singapore. The unaffected controls comprised 270 women attending non-cancer related procedures at the same hospital, 1072 women attending mammogram screening and 541 population-based controls from Singapore.
(a) Deleterious mutations. One of the three deleterious mutations evaluated was detected in the Malaysian breast cancer cases and none were identified in the Malaysian unaffected women, Singaporean breast cancer cases or unaffected women (Table 3 ). Sequence analysis after genotyping also revealed a novel PALB2 frameshift mutation, PALB2 c.1050 delAACA occurring at the same amino acid as the tested mutation, PALB2 c.1050 delAAinsTCT.
The patient with this novel deleterious mutation was a Chinese woman who developed infiltrating ductal carcinoma at age 62, which was positive for the expression of the estrogen receptor and negative for the expression of the progesteroneand HER2 receptors. Her paternal uncle was diagnosed with nasopharyngeal cancer in his 70s (Figure 1 C) .
(b) Missense variants. PALB2 Q559R was determined to be common in the cases and controls (33% and 27% respectively) and this variant was also found in five homozygote unaffected controls (data not shown) showing that this variant is a polymorphism.
Both PALB2 I309V and PALB2 D498Y variants were detected in more than 1% of unaffected women from the Malaysian and Singaporean control cohorts suggesting that these are polymorphisms. Notably, PALB2 I309V was predicted to be benign based on SIFT and Polyphen-2 in-silico predictions whereas PALB2 D498Y was suggested to be possibly damaging in these in-silico analysis.
The remaining three missense mutations were determined to be rare. PALB2 H553Q, predicted to be benign by Polyphen-2 and SIFT, was found in one Malaysian and one Singaporean breast cancer cases (0.1% and 0.2% respectively) and none in the controls. PALB2 P249L and PALB2 E352Q were each found in one breast cancer case and one control. In-silico predictions suggest that P249L may be benign while E352Q is probably damaging.
Four other missense mutations (PALB2 T300I, L763F, A1017T and E1018D) were not tested in the case-control analysis. Variants pathogenicity prediction using in-silico tools suggest that PALB2 T300I is benign while Polyphen-2 predicted PALB2 L763F, PALB2 A1017T and PALB2 E1018D to be probably damaging.
Discussion
In this study, we have analysed the prevalence of PALB2 mutations in a cohort of 122 familial breast cancer cases who do not have alterations in BRCA1 or BRCA2 and found 2 (1.3%) were PALB2 carriers. Notably, we did not examine large chromosomal rearrangements which have previously been reported in other studies [21, 22] and it is possible that these rare genetic changes could have account for additional PALB2 carriers in our population. Although the patients in this study comprised 3 ethnic groups (Chinese, Malay and Indian), all 3 individuals with PALB2 deleterious mutations are Chinese. There was only 4 missense variants found in the Malay and Indian women in this study (compared to 7 in the Chinese women) and this is likely to be because the majority of the women in this study are Chinese. The rarity of germline PALB2 mutations is consistent with that reported in other populations where a mutation prevalence of 0-2% has been reported [17, [23] [24] [25] .
Our study also identified 10 PALB2 missense variants, of which 5 are novel [25, 26] . Of these, 6 were tested in a casecontrol analysis and our results suggest that 5 are likely to be either benign (PALB2 Q559R, I309V, D498Y, P249L and E352Q) or associated with a low increased risk of breast cancer. PALB2 H553Q was found in 2 women affected with breast cancer but not in 1,875 controls. Further analysis of this and other variants [T300I, L763F, A1017T, E1018D] require other methods, including in vitro functional characterization [27] and co-segregation analyses.
Our study uncovered an unusual situation where genotyping of a deleterious mutation (PALB2 c.1050 delAAinsTCT) [13] revealed a distinct mutation (PALB2 c.1050 delAACA) at the same site. Sequence alteration caused by deletion of AACA resulted in mutant SNP that is similar to the interrogated SNP and was therefore regarded as a positive screen. This highlights the limitation of genotyping assay in distinguishing distinct mutations which share a common mutant SNP and therefore, confirmation by conventional sequencing is necessary.
Notably, of the 3 individuals with germline deleterious PALB2 mutations, 2 have moderate family history with Manchester score of 12 and 14 respectively, whereas one developed breast cancer at late age in the absence of any family history of cancer (Manchester score of 2). Indeed, by contrast to BRCA1 and BRCA2 mutation status, we found that there was no association between PALB2 mutation status and family history of breast, ovarian, prostate or pancreatic cancer (data not shown). This is consistent with other studies that have also shown no familial clustering of breast cancer in PALB2 families compared to non-BRCA carrier families [3, 14, 23] . The family members of the PALB2 carrier families were not available for co-segregation analysis and therefore it was not possible to determine the increased risk caused by germline mutation of PALB2 in our population.
In summary, we found 2 germline PALB2 deleterious mutation carriers in 122 high risk non-BRCA1 or BRCA2 breast cancer patients by DNA sequencing and 1 germline carrier in 1406 breast cancer patients by genotyping. Our data shows that PALB2 germline mutations are rare, and are associated with family history of breast cancer in some, but not all families. Table 2 shows all 13 PALB2 germline mutations detected from the sequencing of 122 BRCA-negative individuals and their respective mutation prevalence in the study.
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